Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022.

Aníbal García-Sempere, Estela Giménez, Hermelinda Vanaclocha, Ramón Limón, Salvador Peiró, David Navarro

Abstract read

In one paragraph

Article in Gaceta sanitaria, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aníbal García-SempereHealth Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), València, Spain; Chronicity, Primary Care, and Health Promotion Research Network (RICAPPS), València, Spain. Electronic address: garcia_ani@gva.es.

Estela GiménezMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, València, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Spain.

Hermelinda VanaclochaGeneral Directorate of Public Health, Department of Health, Valencian Government, València, Spain.

Ramón LimónGeneral Directorate of Healthcare, Department of Health, Valencian Government, València, Spain.

Salvador PeiróHealth Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), València, Spain; Chronicity, Primary Care, and Health Promotion Research Network (RICAPPS), València, Spain.

David NavarroMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, València, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Spain; Department of Microbiology, School of Medicine, University of Valencia, València, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo estimate the seroprevalence of SARS-CoV-2 antibodies in the Valencian Community (Spain) in October 2022, when BA.5 was the predominant variant.

methodCross-sectional, region-wide, population-based serosurvey study in 88 randomly selected primary care centers of the Valencian Community.

resultsSeroprevalence of anti-nucleocapsid (indicative of past infection) and total receptor binding domain (indicative of past infection or vaccination) antibodies was 71.0% (confidence interval [CI]: 67.8-74.2) and 98.4% (CI: 97.5-99.3), respectively. 66.7% (CI: 63.4-70.0) of the population shows hybrid immunity, but only 43.2% in those 80 and over.

conclusionsThe high proportion of hybrid immunity detected is relevant for public health strategies. A second vaccination booster was advisable in the elderly population.

Indexed as

COVID-19SARS-CoV-2AgedCross-Sectional StudiesHumansSeroepidemiologic StudiesSpainAdaptive immunityCOVID-19COVID-19 serological testingEspañaEstudios seroepidemiológicosInmunidad adaptativaPruebas serológicas de COVID-19SARS-CoV-2 variantsSeroepidemiologic studiesSpainVariantes de SARS-CoV-2

Identifiers

PMID37331154

DOI10.1016/j.gaceta.2023.102312

PMCPMC10192597

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.